Premier Biomedical adds Adam Dubov to its Scientific Advisory Board

– USA, TX – Premier Biomedical, Inc. (OTCBB: “BIEI”) announced the addition of K. Adam Dubov to their Scientific Advisory Board effective immediately. Mr. Dubov will report to the Chairman of the Scientific Advisory Board, and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.

Mr. Dubov, an FDA (Food & Drug Administration) Regulatory Expert, has extensive experience with FDA processes for all phases of clinical trials or marketing approval from the FDA. He has been involved with both U.S. military and civilian applications related to the review and submissions for approval of clinical trials for drugs (Investigational New Drugs, Abbreviated New Drug Applications), devices (Non-Significant Risk, Investigational Device Exemptions), biologics (Biological Investigational New Drugs, and biosimilars), combination products, and other articles regulated by the FDA.

Mr. Dubov is a subject matter expert in regulations and guidance for all articles regulated by the Food & Drug Administration, and earned his Regulatory Affairs Certification (RAC) in December, 2011. Earlier this year, he successfully completed his recertification as an Institutional Review Board Professional (CIP) as an expert in the ethical review and approval of research with human subjects. Additionally, Mr. Dubov is a member of the Regulatory Affairs Professional Society (RAPS), and of Public Responsibility in Medicine and Research (PRIM&R), and a member of the Order of Barristers.

Mr. Dubov received his Juris Doctorate from University of the Pacific, McGeorge School of Law in Sacramento, California. He holds Master of Business Administration (International Finance) from Trident University International, Culver City, California, and will complete the requirements for a Master of Arts in Bioethics and Health Policy from Loyola University, Neiswanger Institute for Bioethics & Health Policy in Chicago, Illinois in the spring of next year.

William A. Hartman, President and CEO of Premier Biomedical stated, “Adam Dubov brings to Premier Biomedical an impressive knowledge of the medical regulatory maze. We are pleased to welcome him to our Scientific Advisory Board. We will immediately utilize his experience and knowledge to expedite the advancement of treatments and potential cures for traumatic brain injury, breast cancer, Alzheimer’s disease and MS which we are working to develop along with our partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). We are anticipating other significant additions to our Scientific Advisory Board in the very near future.”

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer’s disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company’s common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol “BIEI.”